Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:ATCCode |
none (not approved)
|
| gptkbp:CASNumber |
865854-05-3
|
| gptkbp:chemicalFormula |
C19H14N4O2S
|
| gptkbp:clinicalTrialPhase |
Phase II (as of 2023, for Alzheimer's disease)
|
| gptkbp:developedBy |
gptkb:Alzheimer's_disease
gptkb:progressive_supranuclear_palsy |
| gptkbp:discoveredBy |
gptkb:Noscira
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tideglusib
|
| gptkbp:investigatedBy |
tooth regeneration
|
| gptkbp:IUPACName |
3-[(2,4-dichlorophenyl)methylene]-8-thia-3,4,6,7-tetraazatricyclo[4.3.0.0^{2,7}]nona-1(6),2,4,8-tetraen-9-one
|
| gptkbp:mechanismOfAction |
GSK-3 inhibitor
|
| gptkbp:molecularWeight |
378.41 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL2103837
11288183 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:status |
investigational drug
|
| gptkbp:synonym |
gptkb:NP-12
NP031112 |
| gptkbp:target |
gptkb:glycogen_synthase_kinase-3_beta_(GSK-3β)
|
| gptkbp:UNII |
6Z5B6HVF6O
|
| gptkbp:bfsParent |
gptkb:GSK3
|
| gptkbp:bfsLayer |
6
|